These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34651585)

  • 1. Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.
    Musiek ES; Gomez-Isla T; Holtzman DM
    J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34651585
    [No Abstract]   [Full Text] [Related]  

  • 2. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 3. Revisiting FDA Approval of Aducanumab.
    Alexander GC; Knopman DS; Emerson SS; Ovbiagele B; Kryscio RJ; Perlmutter JS; Kesselheim AS
    N Engl J Med; 2021 Aug; 385(9):769-771. PubMed ID: 34320282
    [No Abstract]   [Full Text] [Related]  

  • 4. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 5. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 6. Alzheimer disease and aducanumab: adjusting our approach.
    Selkoe DJ
    Nat Rev Neurol; 2019 Jul; 15(7):365-366. PubMed ID: 31138932
    [No Abstract]   [Full Text] [Related]  

  • 7. Aducanumab for Alzheimer's disease: A regulatory perspective.
    Nisticò R; Borg JJ
    Pharmacol Res; 2021 Sep; 171():105754. PubMed ID: 34217830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered.
    Rubin R
    JAMA; 2021 Aug; 326(6):469-472. PubMed ID: 34287610
    [No Abstract]   [Full Text] [Related]  

  • 9. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian perspective on Biogen's aducanumab trial.
    Temp AGM; Ly A; van Doorn J; Wagenmakers EJ; Tang Y; Lutz MW; Teipel S
    Alzheimers Dement; 2022 Nov; 18(11):2341-2351. PubMed ID: 35235700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questions EMERGE as Biogen claims aducanumab turnaround.
    Howard R; Liu KY
    Nat Rev Neurol; 2020 Feb; 16(2):63-64. PubMed ID: 31784690
    [No Abstract]   [Full Text] [Related]  

  • 12. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 13. Aducanumab: First Approval.
    Dhillon S
    Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    Anderson TS; Ayanian JZ; Souza J; Landon BE
    JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we learn lessons from the FDA's approval of aducanumab?
    Liu KY; Howard R
    Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J; Chiao P; Bussière T; Weinreb PH; Williams L; Maier M; Dunstan R; Salloway S; Chen T; Ling Y; O'Gorman J; Qian F; Arastu M; Li M; Chollate S; Brennan MS; Quintero-Monzon O; Scannevin RH; Arnold HM; Engber T; Rhodes K; Ferrero J; Hang Y; Mikulskis A; Grimm J; Hock C; Nitsch RM; Sandrock A
    Nature; 2016 Sep; 537(7618):50-6. PubMed ID: 27582220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aducanumab, amyloid, and culture wars.
    Iliffe S; Manthorpe J
    BMJ; 2021 Aug; 374():n2038. PubMed ID: 34413026
    [No Abstract]   [Full Text] [Related]  

  • 18. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

  • 19. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: How Will Aducanumab Approval Impact AD Research?
    Weiner MW; Aisen PS; Beckett LA; Green RC; Jagust W; Morris JC; Okonkwo O; Perrin RJ; Petersen RC; Rivera Mindt M; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ
    J Prev Alzheimers Dis; 2021; 8(4):391-392. PubMed ID: 34585209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.